In most of the type 2 diabetes mellitus (T2DM) patients, metformin is a recommended first-line pharmacotherapy; however, additional therapies are required to sustain glycemic control in most of the patients. Upholding intensive glucose control in the early stage of the disease is imperative and eventually leads to long-term benefits. When metformin fails to attain glycemic control, an additional combination therapy consisting of anti-diabetes agents plays a vital role.
1 The sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors possess corresponding mechanisms of action. Administration of a combination of SGLT-2 inhibitor/DPP-4 inhibitor adjunct to metformin, once-daily, may offer treatment benefits in comparison with the addition of either agent individually as dual therapy. 2 In this regard, Boehringer Ingelheim India and Docplexus have…
